12-18-2015, 12:08 AM
Shkreli, who is now the CEO of biopharmaceutical company KaloBios, has told investors that he plans to price a drug for a neglected parasitic infection somewhere in the $60,000-to-$100,000 per-treatment range, The New York Times' Andrew Pollack reports. If it sounds familiar, that's because the 32-year-old pharma CEO came under fire in September for raising the price of another drug used to treat parasitic infections by 5,000%.
Martin Shkreli seeks FDA approval for Chagas disease - Business Insider
But the very next day was one of the worst. That's when he found out he had a rare type of brain cancer with only a 50 percent chance of survival. And now, he's suing his insurance company for denying him coverage for a type of radiation treatment, proton therapy, which Castro underwent even after the insurance company told him it wouldn't pay for it.
Cofounder with cancer sues insurance - Business Insider
When foxes discovered little penguins on a small Australian island, they nearly wiped the colony out. But a farmer came up with a novel way to protect the birds - and the story has been made into a hit film.
The dogs that protect little penguins - BBC News
“Here is a Classic Conundrum of cause and effect: the men who survive the crushing pace (not to mention lethal diet) of multiple U.S. presidential campaigns and go on to hold one of the most stressful jobs in the world also have a habit of outliving the rest of us,” Gibbs and Duffy write. But why?
Why So Many Presidents Are So Healthy | TIME
But hold on. Something about this story does not add up. In reality, the emerging markets are still emerging. Their rates of economic growth are far ahead of anything the developed world can achieve, their demographics are still in far better shape, and so are their finances. On the issues that genuinely matter such as the rule of law, the ease of doing business and the openness of markets, they are still making rapid progress. Sure, a couple such as South Africa, and perhaps Russia, may well be in deep trouble. But the rest are doing as well as ever. Sooner or later, equity prices are going to catch up with that progress.
Crisis — what crisis? Emerging markets are developing fast - MarketWatch